Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

worldwide are over $5 billion. Nevertheless, available anticoagulants are still inconvenient and associated with an increased risk of bleeding. Improved anticoagulants are therefore required. In particular, agents that allow for improved ease of administration (without requirement for daily dosing and frequent dose adjustment) would fill a significant unmet need.

Legal disclaimer

This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Notes to Editors:

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... NEWPORT NEWS, Va. , Aug. 3, 2015 ... will be joining Orthopaedic & Spine Center ... help them to manage their chronic pain through ... Dr. Robinson is a Fellowship-trained, certified medical ... and pain medicine. His vast experience ranges from ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... BELGRADE, Mont., July 26, 2011 Bacterin ... a leader in the development of revolutionary bone graft material ... call on Thursday, August 11, at 4:30 p.m. Eastern time ... 2011. Financial results will be issued in a press release ...
... America, Inc. today announced plans to debut expanded software ... EasyCell® assistant Automated Cell Imaging Analyzer during ... Conference and Clinical Lab Expo July 24 - 28 ... hematology portfolio can be seen at Sysmex,s exhibit booth, ...
Cached Medicine Technology:Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET 2Sysmex America to Debut Expanded Software Products for Middleware and Cell Image Analysis at AACC 2011 2
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced ... Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, ... the launch of their Readmissions Analytics product was selected as one of four ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... , ... August 03, 2015 , ... The art of ... Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager ... decided to share her cookbook Recipes from My Persian Kitchen with the world. , ...
(Date:8/3/2015)... ... 2015 , ... The U.S. Food and Drug Administration (FDA) recently approved a ... acid, which occurs naturally in the body and helps absorb and breakdown fat cells. ... the body. These are invasive procedures and very expensive for most people. Now with ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Dignity Health ... Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The new ... this year in the West Valley. , “Dr. Baldwin is an excellent leader ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... 8 Medivation, Inc.,(Nasdaq: MDVN ) today announced ... at the 27th Annual J.P. Morgan Healthcare,Conference on Wednesday, January ... Hotel in San Francisco. , Dr. ... programs for Dimebon for Alzheimer,s and Huntington,s diseases and,MDV3100 for ...
... announced today that Erik D. Olson has been named ... & Human Services Policy program. Olson, who was formerly ... Committee on Environment and Public Works, brings nearly 25 ... to Pew. "We are excited to be joined by ...
... be used when assessing traditional risk factors, experts say , , ... or "biomarkers" -- of inflammation may provide useful information when ... says. , "If you are very high or very low ... study lead author Dr. Vijay Nambi, a cardiologist at the ...
... Christine Siu and Jason Brown, Ph.D. Promoted to Vice ... Thomas, McNerney & Partners, a health care venture capital ... companies, today announced the promotion of three members of ... to Principal. Christine Siu and Jason Brown have ...
... ) announces the following Webcast: , What: Heska Corporation ... Year-End 2008 Earnings Conference Call on the Web, ... Where: www.heska.com (click on the Q4 and Year-End 2008 Earnings, ... of this website)., How: Live over the Internet ...
... 8 A proposal by the State of Indiana ... has prompted the 125,000-member American Legion Department of Indiana ... in order to organize and coordinate its members, nearly ... more than $50,000 in direct and in-kind support to ...
Cached Medicine News:Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: